1. United States of America Stocks

  2. •

    Healthcare

  3. •

    Biotechnology
TetraLogic Pharmaceuticals Corporation

TetraLogic Pharmaceuticals Corporation

TLOG
TetraLogic Pharmaceuticals CorporationUS flagOther OTC
0.00
USD
- -
- -
979.00Market Cap
2011 Y
2012 Y
2013 Y
2014 Y
2015 Y
TTM
Revenue per Share
- -
- -
- -
- -
- -
- -
Basic EPS, GAAP
-17.36
-20.26
-10.11
-1.61
-2.1
-1.64
Free Cash Flow per Basic Share
-13.57
-16.45
-5.59
-1.48
-1.48
-0.96
Dividend per Share
- -
- -
- -
- -
- -
- -
Book Value per Share
-42.02
-72.08
-39.15
-5.65
-7.41
-8.16
Tangible Book Value per Share
-41.14
-137.99
22.02
-1.12
-2.01
-2.72
Basic Weighted Avg Shares
1
1
2
22
24
25
Sales/Revenue/Turnover
- -
- -
- -
- -
- -
- -
Operating Margin (%)
- -
- -
- -
- -
- -
- -
Depreciation Expense
- -
- -
- -
- -
- -
- -
Net Income, GAAP
-19
-16
-20
-36
-50
-41
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
Profit Margin (%)
- -
- -
- -
- -
- -
- -
Working Capital
13
2
50
50
18
-7
LT Debt
- -
5
- -
27
28
31
Total Equity
-53
-68
51
33
-6
-31
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)
- -
- -
- -
- -
- -
- -

Capital Structure

FRC

•

in mil. unless spec.
Mar'16
Jun'16
Sep'16
ST Debt
- -
- -
- -
LT Borrowings
29
30
31
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
25
25
25
Market Capitalization
4
7
4

Working Capital

FRC

•

in mil. unless spec.
Mar'16
Jun'16
Sep'16
Total Current Assets
16
9
6
Cash, Cash Equivalents & STI
15
9
6
Accounts Receivable, Net
- -
- -
- -
Inventories
- -
- -
- -
Total Current Liabilities
5
12
13
Payables & Accruals
5
3
4
ST Debt
- -
- -
- -
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
- -
-117.79%
Free Cash Flow
- -
- -
6.34%
Net Income, GAAP
- -
- -
38.28%
Sales/Revenue/Turnover
- -
- -
- -
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2014
- -
- -
- -
- -
- -
2015
- -
- -
- -
- -
- -
2016
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2014
-0.24
-0.42
-0.42
- -
-1.61
2015
-0.56
-0.51
-0.46
- -
-2.1
2016
-0.45
-0.27
-0.35
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2014
- -
- -
- -
- -
- -
2015
- -
- -
- -
- -
- -
2016
- -
- -
- -
- -
- -

Company Description

APIChat
CEO
Yigong Shi
Full Time Employees
29
Sector
Healthcare
Industry
Biotechnology
Address
343 Phoenixville Pike Malvern PA United States of America 19355
IPO Date
Dec 12, 2013
CIK
0001361248
Website
tetralogicpharma.com
Similar Companies
Cerevel Therapeutics Holdings, Inc. (CERE)
Erasca, Inc. (ERAS)
Emmaus Life Sciences, Inc. (EMMAW)
Midatech Pharma plc (MTP)
Mineralys Therapeutics, Inc. (MLYS)
Reviva Pharmaceuticals Holdings, Inc. (RVPHW)
Business
TetraLogic Pharmaceuticals Corporation TetraLogic Pharmaceuticals Corporation (TLOG) is a clinical-stage biopharmaceutical company that discovers, develops, and seeks to commercialize novel small molecule therapeutics targeting oncology and infectious diseases; its lead product candidates include birinapant, a SMAC mimetic that antagonizes inhibitor of apoptosis proteins to induce tumor cell death in hematological malignancies and solid tumors such as acute myeloid leukemia, pancreatic, and ovarian cancers, and SHAPE (suberohydroxamic acid phenyl ester), a proprietary topical histone deacetylase inhibitor for early-stage cutaneous T-cell lymphoma. The company maintains research collaborations, including with the Walter and Eliza Hall Institute of Medical Research on SMAC-mimetics like birinapant for infectious disease applications and past partnerships such as with Merck on birinapant combinations with pembrolizumab in solid tumors. Founded in 2001 and headquartered in Malvern, Pennsylvania, TetraLogic Pharmaceuticals Corporation previously known as Gentara Corporation until its name change in January 2006, acquired Shape Pharmaceuticals to expand its oncology pipeline with SHAPE and licensed birinapant assets to Medivir in 2016 amid clinical challenges, with its lead candidates now listed in discontinued or pending statuses across anemia, alopecia areata, and other indications as of recent pipeline updates.